GBP510
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.[1][2][3][4][5]
It was originally developed by the Institute for Protein Design of the University of Washington.[6][7]
The phase III clinical trial involves 4,037 participants. Should the trial confirm GBP510's efficacy and safety, the vaccine is expected to be approved in the first half of 2022.[8][9][10][11]
A booster dose trial is being planned. The booster is to be given 6 months after the second dose is administered.[11]
References[edit]
- ^ "SK COVID-19 Vaccine "GBP510" CEPI "Wave2" (next-generation vaccine)ed as the first development support target". SK Bioscience. 10 December 2020. Retrieved 28 July 2021.
- ^ "CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 9 December 2020. Retrieved 28 July 2021.
- ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 11 February 2021. NCT04750343. Retrieved 22 April 2021.
- ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 8 February 2021. NCT04742738. Retrieved 22 April 2021.
- ^ Moon-hee C (11 June 2021). "SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington". Business Korea. Retrieved 28 July 2021.
- ^ "Two nanoparticle vaccines enter clinical trials – Institute for Protein Design". Retrieved 18 August 2021.
- ^ "CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine". 24 May 2021.
- ^ "SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing".
- ^ "SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial". 31 August 2021.
- ^ SK Bioscience Co., Ltd. (14 October 2021). "A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ a b "IVI and SK bioscience Complete Recruitment for Phase III Clinical Trial of SKBS' COVID-19 Vaccine". Retrieved 7 February 2022.
Scholia has a profile for GBP510 (Q108044254). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=GBP510&oldid=1070507626"
Hidden categories:
- CS1 errors: missing periodical
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from July 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles